XNCR Xencor Inc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1326732 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY19.8%
TTM net income YoY15.1%
TTM EPS YoY9.8%
Revenue 3-yr CAGR11.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-72.7%
Net margin-58.8%
FCF margin-88.0%
EBITDA margin-67.9%
Returns
ROE-19.9%
ROA-14.4%
ROIC (approx.)-17.4%
Asset turnover0.24x
Leverage & solvency
Liabilities / assets27.3%
Debt / equity0.17x
Current ratio6.54x
Interest coverage-6.19x
Cash quality & payout
Operating cash flow / net income1.46x
Accruals ratio6.6%
Payout ratio—
Capex / revenue2.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $116.52M | $51.22M | $4.52M | $28.24M | $21.00M | $43.61M | $32.73M | $70.02M |
| R&D expense | $84.30M | $71.91M | $64.67M | $64.82M | $54.37M | $61.66M | $58.58M | $51.06M |
| SG&A expense | $9.36M | $16.38M | $17.71M | $17.04M | $14.15M | $15.12M | $17.34M | $14.91M |
| Operating income | $22.86M | -$37.07M | -$77.86M | -$53.63M | -$47.52M | -$33.17M | -$43.18M | $4.05M |
| Interest expense | $4.11M | $7.35M | $4.70M | $7.35M | $7.67M | $8.24M | $8.66M | $33.93M |
| Pretax income | $39.26M | -$21.92M | -$128.64M | -$4.27M | -$6.03M | -$31.07M | -$48.27M | -$52.63M |
| Income tax | -$175,000 | -$190,000 | $280,000 | $2.39M | $0 | -$250,000 | $367,000 | $1.50M |
| Net income | $39.44M | -$21.73M | -$128.92M | -$6.65M | -$6.03M | -$30.82M | -$48.42M | -$53.48M |
| EBITDA | $24.96M | -$34.77M | -$75.30M | -$51.05M | -$45.12M | -$30.77M | -$40.49M | $7.04M |
| EPS (basic) | 0.52 | -0.29 | -1.71 | — | -0.08 | -0.41 | -0.66 | — |
| EPS (diluted) | 0.50 | -0.29 | -1.71 | — | -0.08 | -0.41 | -0.66 | — |
| Weighted avg. shares (diluted) | 78.35M | 75.86M | 75.25M | — | 74.41M | 74.28M | 73.67M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $59.62M | $44.66M | $14.17M | $54.07M | $28.29M | $44.73M | $39.96M | $41.26M |
| Receivables | $64.84M | $42.23M | $12.00M | $29.30M | $21.80M | $47.55M | $37.78M | $60.85M |
| Current assets | $498.66M | $523.21M | $482.86M | $599.82M | $518.44M | $513.15M | $521.27M | $577.60M |
| PP&E, net | $49.78M | $50.01M | $51.49M | $53.31M | $54.59M | $56.79M | $58.81M | $59.80M |
| Intangibles | $5.05M | $6.52M | $7.60M | $8.38M | $9.47M | $11.25M | $13.36M | $18.48M |
| Total assets | $770.50M | $724.96M | $736.85M | $875.50M | $868.81M | $879.42M | $904.69M | $951.95M |
| Current liabilities | $76.27M | $81.86M | $73.46M | $95.91M | $86.48M | $96.08M | $88.44M | $87.43M |
| Short-term debt | $23.13M | $27.36M | $26.41M | $43.27M | $45.36M | $50.29M | $52.54M | $48.45M |
| Long-term debt | $71.93M | $77.54M | $82.12M | $76.48M | $87.78M | $94.74M | $101.84M | $115.16M |
| Total debt | $95.06M | $104.89M | $108.53M | $119.75M | $133.14M | $145.02M | $154.38M | $163.61M |
| Total liabilities | $210.07M | $221.73M | $221.21M | $239.91M | $243.50M | $259.07M | $264.81M | $277.92M |
| Shareholders' equity | $560.43M | $503.23M | $515.63M | $635.59M | $625.32M | $620.35M | $639.87M | $677.61M |
| Net debt | $35.44M | $60.23M | $94.36M | $65.68M | $104.85M | $100.29M | $114.42M | $122.34M |
| Shares outstanding | 74.76M | 74.33M | 74.06M | 71.87M | 71.34M | 71.30M | 71.14M | 70.26M |
| Cash flow statement | ||||||||
| Operating cash flow | $2.64M | -$55.66M | -$67.63M | -$51.71M | -$30.82M | -$36.37M | -$16.22M | -$55.58M |
| Capital expenditure | $1.80M | $538,000 | $610,000 | $1.14M | $183,000 | $383,000 | $1.44M | $1.66M |
| Free cash flow | $838,000 | -$56.20M | -$68.24M | -$52.85M | -$31.00M | -$36.75M | -$17.66M | -$57.24M |
| Investing cash flow | $7.33M | $85.12M | $26.68M | $71.17M | $14.67M | $40.48M | $13.67M | $57.25M |
| Financing cash flow | $9.99M | $1.03M | $950,000 | $6.32M | $0 | $662,000 | $1.25M | $10.17M |
| Depreciation & amortization | $2.10M | $2.30M | $2.57M | $2.58M | $2.40M | $2.40M | $2.69M | $2.99M |
| Stock-based compensation | $9.43M | $9.19M | $9.56M | $10.19M | $10.09M | $10.74M | $12.21M | $12.33M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.